Medpage Today on MSN3d
Higher Comorbidity Burden in Multiple Sclerosis Tied to Worse Outcomes"Those with the highest burden of comorbidity had over a 30% increased risk of having disability worsening," Salter said. "In ...
The FDA approved Ocrevus Zunovo, a subcutaneous formulation of Ocrevus, for adults with relapsing forms of MS and PPMS ...
Patients will be able to get a 10 minute injection of the Roche drug, instead of an hours-long infusion. Novartis already has ...
The FDA has approved Roche's Ocrevus Zunovo for relapsing and primary progressive multiple sclerosis, offering the first ...
High-dose cholecalciferol (vitamin D) is safe and can nearly double the time it takes for clinically isolated syndrome to ...
Shares of TG Therapeutics made new 52-week highs this week, helped in part by new Briumvi data presentations at ECTRIMS and ...
When Roche's Genentech gained approval for Ocrevus in 2017, the first-in- | On the same day that Roche gained an FDA approval ...
The treatment, called Ocrevus Zunovo, was approved as a biannual, approximately 10-minute, under-the-skin injection for patients with relapsing multiple sclerosis and primary progressive multiple ...
Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any breaking news developments ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback